The FDA granted approval to Eli Lilly and Company’s mirikizumab-mrkz (Omvoh) for Crohn disease, expanding its treatment reach ...

The pharmaceutical industry could generate more than $1.2 trillion in global sales in 2025, according to Statista. The cancer segment alone is expected to generate $208 billion in sales this year. The ...

Wrist-worn devices can predict imminent inflammatory and symptomatic inflammatory bowel disease flare-ups as far in advance ...

In a large cohort of patients with autoimmune diseases, treatment with biologic disease-modifying antirheumatic drugs was ...

Women with inflammatory bowel disease who delivered a twin gestation pregnancy had higher rates of preterm delivery and ...

Overall, the use of 5-aminosalicylic acid (5-ASA) in combination with ustekinumab (UST) did not provide a significant benefit in patients with inflammatory bowel disease (IBD). Evidence Rating Level: ...

Galapagos (0JXZ – Research Report) received a Sell rating and a €22.00 price target from Barclays analyst Emily Field today. The company’s ...

Peak incidence of IBD corresponds with prime reproductive years for women, yet many do not discuss contraception with IBD specialists.

The Food and Drug Administration has approved Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn disease in adults.

As people age, vertical nail ridges, known as onychorrhexis, can form due to nutritional deficiencies, anemia, digestive ...

Odyssey Therapeutics is a promising biotech firm poised for IPO success with a focus on inflammatory and autoimmune diseases ...

Many with Crohn’s disease or ulcerative colitis sacrifice essential purchases like food and clothing for healthcare, survey ...